BTIG analyst Ryan Zimmerman reiterated a Neutral rating on Globus Medical (NYSE: GMED)The analyst comments "GMED's 3Q25 results proved to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE